Literature DB >> 3167778

Extended resection for primary colorectal carcinoma involving adjacent organs or structures.

S F Heslov1, D B Frost.   

Abstract

Involvement of adjacent organs by colorectal cancer has been associated historically with poor local control and survival. This can be improved by en bloc extended resection. A retrospective review was done of 58 patients who underwent this procedure. The operative mortality was 5%. Cases were divided into Gunderson-Sosin Stages B3 and C3. Five-year survival was markedly better for Stage B3 (64% versus 11%). Regardless of stage, local recurrence was increased, and 5-year survival decreased for those cancers with carcinomatous adhesions. At surgery, lesions cannot be staged accurately into C3 or B3 cancers. All such lesions should be resected. The B3 patients have a significant chance for cure, and C3 patients will have good local control despite their dismal 5-year survival.

Entities:  

Mesh:

Year:  1988        PMID: 3167778     DOI: 10.1002/1097-0142(19881015)62:8<1637::aid-cncr2820620830>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Surgical resection of locally advanced primary transverse colon cancer--not a worse outcome in stage II tumor.

Authors:  Hsin-Yuan Hung; Chien-Yuh Yeh; Chung-Rong Changchien; Jinn-Shiun Chen; Chung-Wei Fan; Reiping Tang; Pao-Shiu Hsieh; Wen-Sy Tasi; Yau-Tong You; Jeng-Fu You; Jeng-Yi Wang; Jy-Ming Chiang
Journal:  Int J Colorectal Dis       Date:  2011-01-29       Impact factor: 2.571

2.  Thirty-day outcomes in patients treated with en bloc colectomy and pancreatectomy for locally advanced carcinoma of the colon.

Authors:  Ian M Paquette; Brian R Swenson; Mary R Kwaan; Anders F Mellgren; Robert D Madoff
Journal:  J Gastrointest Surg       Date:  2011-09-29       Impact factor: 3.452

3.  Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients.

Authors:  Thomas Lehnert; Mascha Methner; Andreas Pollok; Anja Schaible; Ulf Hinz; Christian Herfarth
Journal:  Ann Surg       Date:  2002-02       Impact factor: 12.969

4.  [Multivisceral resection of advanced colorectal cancer].

Authors:  K H Schultheis; S Ruckriegel; C Gebhardt
Journal:  Langenbecks Arch Chir       Date:  1994

5.  Robotic-assisted multivisceral resection for rectal cancer: short-term outcomes at a single center.

Authors:  H Hino; T Yamaguchi; Y Kinugasa; A Shiomi; H Kagawa; Y Yamakawa; M Numata; A Furutani; Y Yamaoka; S Manabe; T Suzuki; S Kato
Journal:  Tech Coloproctol       Date:  2017-11-13       Impact factor: 3.781

6.  Outcome of surgical management of the bladder in advanced colorectal cancer.

Authors:  Feng Gao; Yun-fei Cao; Li-sheng Chen; Sen Zhang; Zong-jiang Tang; Jun-lin Liang
Journal:  Int J Colorectal Dis       Date:  2006-03-01       Impact factor: 2.571

7.  Analysis of the prognostic effectiveness of a multivisceral resection for locally advanced colorectal cancer.

Authors:  Sejin Park; Yun Sik Lee
Journal:  J Korean Soc Coloproctol       Date:  2011-02-28

8.  Factors associated with local recurrence after neoadjuvant chemoradiation with total mesorectal excision for rectal cancer.

Authors:  Nam-Kyu Kim; Young-Wan Kim; Byung-Soh Min; Kang-Young Lee; Seung-Kook Sohn; Chang-Hwan Cho
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

9.  Management of patients with carcinoma of the right colon invading the duodenum or pancreatic head.

Authors:  David Fuks; Patrick Pessaux; Jean-Jacques Tuech; François Mauvais; Olivier Bréhant; Frédéric Dumont; Denis Chatelain; Thierry Yzet; Jean-Paul Joly; Benoit Lefebure; Sushil Deshpande; Jean-Pierre Arnaud; Pierre Verhaeghe; Jean-Marc Regimbeau
Journal:  Int J Colorectal Dis       Date:  2008-01-24       Impact factor: 2.571

10.  En bloc resection for right colon cancer directly invading duodenum or pancreatic head.

Authors:  Won-Suk Lee; Woo Yong Lee; Ho-Kyung Chun; Seong-Ho Choi
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.